Protein Variants | Comment | Organism |
---|---|---|
H499A/E501A | site-directed mutagenesis, inactive mutant | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(R)-2-(1-(1-benzoylpiperidin-3-yl)-1H-1,2,3-triazol-4-yl)isonicotinic acid | - |
Homo sapiens | |
1-(3-(ethylsulfonyl)phenyl)-2-(4-(pyridin-2-yl)thiazol-2-yl)ethan-1-one | - |
Homo sapiens | |
1-(3-(methylsulfonyl)phenyl)-2-(4-(pyridin-2-yl)thiazol-2-yl)ethan-1-one | - |
Homo sapiens | |
1-(4-(methylsulfonyl)phenyl)-2-(4-(pyridin-2-yl)thiazol-2-yl)ethan-1-one | - |
Homo sapiens | |
1-phenyl-2-(4-(pyridin-2-yl)thiazol-2-yl)ethan-1-one | - |
Homo sapiens | |
2-(1-hydroxyvinyl)isonicotinic acid | - |
Homo sapiens | |
2-(2-aminothiazol-4-yl)isonicotinamide | - |
Homo sapiens | |
2-(2-aminothiazol-4-yl)isonicotinic acid | - |
Homo sapiens | |
2-(2-benzamidothiazol-4-yl)isonicotinic acid | - |
Homo sapiens | |
2-(2-methylthiazol-4-yl)isonicotinic acid | - |
Homo sapiens | |
2-(thiazol-4-yl)isonicotinic acid | - |
Homo sapiens | |
3-((2-(pyridin-2-yl)-6-(1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)pyrimidin-4-yl)amino)propanoic acid | - |
Homo sapiens | |
3-(2-((2-aminoethyl)carbamoyl)pyridin-4-yl)benzoic acid | - |
Homo sapiens | |
3-(methylsulfonyl)-N-(4-(pyridin-3-yl)thiazol-2-yl)benzamide | - |
Homo sapiens | |
4-((methyl((1-(4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)methyl)amino)methyl)benzonitrile | - |
Homo sapiens | |
4-((methyl(2-(1-(4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)ethyl)amino)methyl)benzonitrile | - |
Homo sapiens | |
4-(1-(2-(1-(4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)ethyl)piperidin-4-yl)benzonitrile | - |
Homo sapiens | |
4-(methylsulfonyl)-N-(4-(pyridin-3-yl)thiazol-2-yl)benzamide | - |
Homo sapiens | |
4-(pyridin-3-yl)thiazol-2-amine | - |
Homo sapiens | |
8-(((furan-2-ylmethyl)amino)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-((4-(pyridin-2-yl)piperazin-1-yl)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-((4-methylpiperazin-1-yl)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-((4-phenylpiperazin-1-yl)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-((benzylamino)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-((dimethylamino)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(1-methyl-1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(2-aminothiazol-4-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(((3,4-dichlorobenzyl)(methyl)amino)methyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-((dimethylamino)methyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-((methyl(4-(methylsulfonyl)benzyl)amino)methyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-((4-fluorobenzyl) (methyl)amino)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-((5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(2,4-difluorophenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(2-chlorophenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(3,4-dichlorobenzyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(3,5-dichlorophenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | substitution from C4 of the pyrazole moiety allows access to the histone peptide substrate binding site, incorporation of a conformationally constrained 4-phenylpiperidine linker gives derivatives such as 8-(4-(2-(4-(3-chlorophenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one which demonstrates equipotent activity versus the KDM4 (JMJD2) and KDM5 (JARID1) subfamily demethylases, selectivity over representative exemplars of the KDM2, KDM3, and KDM6 subfamilies, and cellular permeability in the Caco-2 assay | Homo sapiens | |
8-(4-(2-(4-(3,5-difluorophenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(3-chlorophenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | substitution from C4 of the pyrazole moiety allows access to the histone peptide substrate binding site, incorporation of a conformationally constrained 4-phenylpiperidine linker gives derivatives such as 8-(4-(2-(4-(3-chlorophenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one which demonstrates equipotent activity versus the KDM4 (JMJD2) and KDM5 (JARID1) subfamily demethylases, selectivity over representative exemplars of the KDM2, KDM3, and KDM6 subfamilies, cellular permeability in the Caco-2 assay, and inhibition of H3K9Me3 and H3K4Me3 demethylation in a cell-based assay | Homo sapiens | |
8-(4-(2-(4-(3-methoxybenzyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(4-(methylsulfonyl)phenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(4-(trifluoromethyl)benzyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(4-chlorobenzyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(4-chlorophenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(4-fluorobenzyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(4-fluorophenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(4-methoxyphenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(pyridin-3-ylmethyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(pyridin-4-yl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-(thiophen-2-yl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-benzylpiperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(2-(4-phenylpiperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(hydroxymethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(piperidin-1-ylmethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(4-(pyrrolidin-1-ylmethyl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(piperidin-1-ylmethyl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-(thiazol-4-yl)pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
8-chloropyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens | |
lithium 2-(((furan-2-ylmethyl)amino)methyl)isonicotinate | - |
Homo sapiens | |
lithium 2-((benzylamino)methyl)isonicotinate | - |
Homo sapiens | |
additional information | discovery and synthesis of N-substituted 4-(pyridin-2-yl)thiazole-2-amine derivatives and their subsequent optimization, guided by structure-based design, to give 8-(1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-ones, a series of potent JmjC histone N-methyl lysine demethylase (KDM) inhibitors which bind to Fe(II) in the active site. No inhibition by 4-(pyridin-2-yl)thiazol-2-amine; discovery and synthesis of N-substituted 4-(pyridin-2-yl)thiazole-2-amine derivatives and their subsequent optimization, guided by structure-based design, to give 8-(1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-ones, a series of potent JmjC histone N-methyl lysine demethylase (KDM) inhibitors which bind to Fe(II) in the active site. No inhibition by 4-(pyridin-2-yl)thiazol-2-amine, 4-((methyl((1-(4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)methyl)amino)methyl)benzonitrile, and 4-((methyl(2-(1-(4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)ethyl)amino)methyl)benzonitrile, poor inhibition by 8-((4-phenylpiperazin-1-yl)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one | Homo sapiens | |
pyrido[3,4-d]pyrimidin-4(3H)-one | - |
Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
nucleus | - |
Homo sapiens | 5634 | - |
Metals/Ions | Comment | Organism | Structure |
---|---|---|---|
Fe2+ | dependent on, active site bound, required for activity | Homo sapiens |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
histone H3 N6,N6,N6-trimethyl-L-lysine4 + 2-oxoglutarate + O2 | Homo sapiens | - |
histone H3 N6,N6-dimethyl-L-lysine4 + succinate + formaldehyde + CO2 | - |
? | |
histone H3 N6,N6-dimethyl-L-lysine4 + 2-oxoglutarate + O2 | Homo sapiens | - |
histone H3 N6-methyl-L-lysine4 + succinate + formaldehyde + CO2 | - |
? | |
histone H3 N6-methyl-L-lysine4 + 2-oxoglutarate + O2 | Homo sapiens | - |
histone H3 L-lysine4 + succinate + formaldehyde + CO2 | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P41229 | - |
- |
Homo sapiens | Q9UGL1 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
Caco-2 cell | - |
Homo sapiens | - |
HeLa cell | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
histone H3 N6,N6,N6-trimethyl-L-lysine4 + 2-oxoglutarate + O2 | - |
Homo sapiens | histone H3 N6,N6-dimethyl-L-lysine4 + succinate + formaldehyde + CO2 | - |
? | |
histone H3 N6,N6-dimethyl-L-lysine4 + 2-oxoglutarate + O2 | - |
Homo sapiens | histone H3 N6-methyl-L-lysine4 + succinate + formaldehyde + CO2 | - |
? | |
histone H3 N6-methyl-L-lysine4 + 2-oxoglutarate + O2 | - |
Homo sapiens | histone H3 L-lysine4 + succinate + formaldehyde + CO2 | - |
? |
Synonyms | Comment | Organism |
---|---|---|
JARID1B | - |
Homo sapiens |
JARID1C | - |
Homo sapiens |
KDM5B | - |
Homo sapiens |
KDM5C | - |
Homo sapiens |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
22 | - |
assay at room temperature | Homo sapiens |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.5 | - |
assay at | Homo sapiens |